24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost

References

• SommerATielschJMKatzJRelationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye SurveyArch Ophthalmol1991109109010951867550
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study. A randomized trial determines that topical hypotensive medication delays or prevents the onset of primary-open angle glaucomaArch Ophthalmol200212070171312049574
   PubMed Web of Science ®Google Scholar
• GaasterlandDEEdererFBeckAThe Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deteriorationAm J Ophthalmol200013042944011024415
   PubMed Web of Science ®Google Scholar
• LichterPRMuschDCGillespieBWCIGTS Study Group: interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgeryOphthalmology20011081943195311713061
   PubMed Web of Science ®Google Scholar
• Japan Glaucoma SocietyGuidelines for glaucoma 2004 Accessed on Jan 10, 2009. Available from: http://www.ryokunaisho.jp/
   Google Scholar
• AlwardWLMedical management of glaucomaN Engl J Med1998339129813079791148
   PubMed Web of Science ®Google Scholar
• Kobelt-NguyenGGerdthamUGAlmACosts of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational chart review of newly diagnosed patients in Sweden and the United StatesJ Glaucoma19987951049559495
   PubMed Web of Science ®Google Scholar
• CamrasCBAlmAWatsonPLatanoprost, a prostaglandin analog, for glaucoma therapy: efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study GroupsOphthalmology1996103191619248942890
   PubMed Web of Science ®Google Scholar
• SilverLHClinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study GroupAm J Ophhthalmol1998126400408
   PubMed Web of Science ®Google Scholar
• BrubakerRFIngnamCJSchoffEOComparison of the efficacy of betaxalol–brinzolamide and timolol–dorzolamide as suppressors of aqueous humor flow in human subjectsOphthalmology200010728328710690826
   PubMed Web of Science ®Google Scholar
• AlmAStjernschantzJEffects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Scandinavian Latanoprost Study GroupOphthalmology1995102174317529098273
   PubMed Web of Science ®Google Scholar
• CamrasCBComparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six month masked, multicenter trial in the United States. The United States Latanoprost Study GroupOphthalmology19961031381478628544
   PubMed Web of Science ®Google Scholar
• MishimaHKMasudaKKitazawaYA comparison of latanoprost and timolol in primary open angle glaucoma and ocular hypertension. A 12 week studyArch Ophthalmol19961149299328694726
   PubMed Web of Science ®Google Scholar
• WatsonPStjernschantzJA six month, randomized, double masked study comparing latanoprost with timolol in open angle glaucoma and ocular hypertension. The Latanoprost Study GroupOphthalmology19961031261378628543
   PubMed Web of Science ®Google Scholar
• AlmAWidengardIKjellgrenDLatanoprost administrated once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timololBr J Ophthalmol19957912167880782
   PubMed Web of Science ®Google Scholar
• HigginbothamEJFeldmanRStilesMFixed Combination Investigative Study Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trialArch Ophthalmol200212091592212096962
   PubMed Web of Science ®Google Scholar
• O’ConnorDJMartoneJFMeadAAdditive intraocular pressure lowering effect of various medications with latanoprostAm J Ophthalmol200213383683712036683
   PubMed Web of Science ®Google Scholar
• ShojiNOgataHSuyamaHIntraocular pressure lowering effect of brinzolamide 1% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label studyCurr Med Res Opin20052150350715899098
   PubMed Web of Science ®Google Scholar
• IshikawaSNakamuraYNakamuraYEfficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12 week studyClin Ophthalmol2008270370819668419
   PubMedGoogle Scholar
• TamerCOksuzHCircadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprostOphthalmic Res200739243117164574
   PubMed Web of Science ®Google Scholar
• MichaudJEFrirenBInternational Brinzolamide Adjunctive Study GroupComparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertensionAm J Ophthalmol200113223524311476685
   PubMed Web of Science ®Google Scholar
• TsukamotoHNomaHMatsuyamaSThe efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a β-blocker in patients with glaucomaJ Ocular Pharmacol Ther200521170173
   PubMed Web of Science ®Google Scholar
• TsukamotoHNomaHMukaiSThe efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamideJ Ocular Pharmcol Ther200521395399
   PubMed Web of Science ®Google Scholar
• SilverLHOcular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. The Brinzolamide Comfort Study GroupSurv Ophthalmol200044S141S14510665516
   PubMed Web of Science ®Google Scholar
• KitazawaYAzumaIIwataKDorzolamide, a topical carbonic anhydrase inhibitor: A two-week dose-response study in patients with glaucoma or ocular hypertensionJ Glaucoma19943275279
   PubMedGoogle Scholar